In 1255 critically ill adults with COVID-19, intermediate-dose heparin did not improve organ support-free days vs standard low-dose thromboprophylaxis (OR 1.06; probability of benefit 73.5%). Survival 77.1% vs 76.7%; major bleeding 1.7% vs 2.1%.
RCTn = 1,255
Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators et al. Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial